An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression

BACKGROUND: Patients who receive immunotherapeutics may develop an atypical response pattern, which warrants further investigation into the potential benefits and risks for patients who continue immunotherapy beyond RECIST-defined disease progression. METHODS: A pooled analysis including all submiss...

Descripción completa

Detalles Bibliográficos
Autores principales: Beaver, Julia A., Hazarika, Maitreyee, Mulkey, Flora, Mushti, Sirisha, Chen, Huanyu, He, Kun, Sridhara, Rajeshwari, Goldberg, Kirsten B., Chuk, Meredith K., Chi, Dow-Chung, Chang, Jennie, Barone, Amy, Balasubramaniam, Sanjeeve, Blumenthal, Gideon M., Keegan, Patricia, Pazdur, Richard, Theoret, Marc R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806609/
https://www.ncbi.nlm.nih.gov/pubmed/29361469
http://dx.doi.org/10.1016/S1470-2045(17)30846-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806609/
https://www.ncbi.nlm.nih.gov/pubmed/29361469
http://dx.doi.org/10.1016/S1470-2045(17)30846-X

Ejemplares similares